Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Rafael Holdings, Inc. Class B Common Stock

$2.73

+0.1 (+3.8%)

F 13Pipeline Score Tools & Services · Pre-Clinical
Market Cap
65.55 M
EPS
-0.78
P/E Ratio
-1.61 $
Value Trade
74.03 K
SEC Financials
Q4 2025

  • Dilution Risk

    25%

  • Revenue

    240.00 K

  • R&D Expenses

    7.48 M

  • Operating CF

    -6.81 M

  • Total Assets

    105.38 M

  • Total Liabilities

    16.20 M

  • Equity

    85.18 M

  • D/E Ratio

    12,345

%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Stable

  • Cash Position

    45.54 M

  • Monthly Burn

    2.27 M

  • Runway

    17.1 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Dec 12, 2025
Overview
Volume
386.38 K
52 Week Range
1.12 - 3.19
% held by Insiders
32.44 %
% held by Institutions
6.77 %
Enterprise Value
32.52 M
Total Shares
50.94 M
Short %
0.19 %
Float Shares
30.56 M
Company Description
HQ: 520 BROAD STREET, NEWARK, NJ, ...
Employees:23
https://www.rafaelholdings.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
F13
Pipeline Score
-
Pipeline Value
Valuation Signal
0
Drugs Scored
—
rNPV / MCap
Top 10%
Micro Cap
(rank 815 of 905)
Percentile Rank
Rafael Holdings, Inc. Class B Common Stock has significant pipeline risk (13/100).
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in RFL
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RFL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RFL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RFL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
RFL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
RFL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-RFL
Jun 11, 2026
RFLPhases

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings reported its financial results for Q3 FY 2026, highlighting the completion of its pivotal Phase 3 TransportNPC trial. The company anticipates submitting its New Drug Application in the latter half of 2026, aiming to address the unmet needs of Niemann-Pick Disease Type C1. Despite a net loss of $4.2 million, the company sees potential for long-term shareholder value.

Read more →
-RFL
Jun 10, 2026
RFLPhases

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings has completed the last patient visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ aimed at treating Niemann-Pick Disease Type C. The study involved 94 patients across 27 sites globally. Topline results are expected in the second half of 2026, with the company planning to submit an NDA following a pre-NDA meeting with the FDA.

Read more →
Competitive Position
How RFL ranks across every disease it competes in
Competitive Position is a premium feature
See how RFL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial